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ABSTRACT 
In Ayurveda, health means the state of Doshasamya, Agnisamya, Dhatusamya and Samanya Malkriya as well as wellness of Atmendriya and Mana1, 
which according to Acharya Charak is necessary to achieve Dharma, Artha, Kama & Moksha2, the ultimate aim of life. But it has become quite 
difficult due to the various health obstacles experienced by men during his routine life. The disease Vatarakta is one of them and the number of 
Vatarakta patient are increasing day by day. The status of Vatarakta is often compared with Gouty Arthritis in the allied sciences. As far as the 
treatment of Vatarakta/Gouty Arthritis is concerned various research works conducted from time to time, which had shown encouraging result, 
but still there are many Ayurvedic medicine whose effect has to be established in the management of Vatarakta/Gouty Arthritis based on latest 
scientific parameters. Acharya Charak has advocated the use of different Ghrit Yog, Tail Yog, Lepa, Pradeha, etc for external application in 
different types of Vatarakta for relieving pain, swelling, stiffness, burning, itching, etc. So, for this research work we selected Patoladi Kwath from 
Susrut Chikitsa Sthana 5 and Rasnadi Pradeh from Charak Sutra Sthana 3 to evaluate their efficacy in the management of Vatarakta (w.s.r. to 
Gouty Arthritis). For this research work 56 diagnosed patient of Vatarakta having age of 21 to 60 years were registered and sequentially 
randomized into two parallel groups. Leaving 6 dropout (3 from each group), 25 patients of group A were treated with 40 ml Patoladi kwath 2 
times a day after meal for 90 days and 25 patients of group B were treated with 40 ml Patoladi kwath 2 times a day after meal with Rasnadi 
Praddeh for local application over affected joint in the evening for 90 days. The result of the treatment was accessed based on the improvement 
in terms of symptomatic relief and improvement in terms of Lab investigation i.e, decrease in Serum Uric Acid level and ESR. 
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INTRODUCTION 
Vatarakta is a disease where both Vata and Rakta are 
afflicted by distinct etiological factors. According to Acharya 
Charak, when the vitiated Vata Dosha circulates through the 
Srotus the pre-vitiated Rakta forms an Avarana over Vata 
and further agitates Vata Dosha. Vitiated Vata and Rakta 
together lead to a complex effect on the joint and produces 
Vatarakta3. According to Acharya Susruta, the process of 
disease initiates from Padamula i.e. feet and sometimes from 
Karamula i.e. hand and spreads throughout the body like 
Mushika vish4 (rat poison). 
Vatarakta is one of the burning health problems of the 
present era as the number of Vatarakta patient are 
increasing day by day. The dramatic increase is presumably 
due to lifestyle and food habits. Now a day lifestyle is 
becoming more & more luxurious. People do not take proper 
diet and do not follow proper dietary rules as described in 
Ayurveda under Dincharya, Ritucharya, etc. Improper dietary 
habits such as Adhyashana, Virudhashana, Ahitashana, etc 
and use of meat of aquatic and marshy animals, more 
consumption of fast food, junk food, high protein diet, less 
tendency to exercise, more vehicle riding, long term vehicle 
riding over damaged road have increased the number of 
Vatarakta patient. 
The disease Vatarakta has been described in Garunpuran, 
Agnipuran and in almost all Ayurvedic classics such as- 
Brihatrayi, Laghutrayi, Vangsena, Chakradutta and Bhaisajya 
Ratnavali, etc, which shows that this disease was prevalent 
widely in early era too. 
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The status of Vatarakta is often compared with Gout/Gouty 
Arthritis in the allied sciences due to the outstanding 
similarities and also because in previous research works 
hyperuricaemia has been observed as a common feature in 
patients of Vatarakta. Gout is a clinical syndrome and is a 
type of metabolic disease in which clinical manifestations are 
associated with tissue deposition of crystals of Monosodium 
Urate Monohydrate (MSUM) from hyperuricemic body fluids. 
Acute Gout affects mainly joints, synovial membrane, 
articular cartilages, tendon sheaths and burse but the local 
aggregation of Monosodium Urate Monohydrate crystals 
may also occur in non-articular cartilage. Acute Gouty attack 
mostly initiates from great toe but it may sometime initiate 
from ankle, knee, wrist, finger, elbow, etc. and is 
characterized by rapid onset of pain, swelling, redness, 
tenderness, itching and burning sensation and discoloration 
of skin over affected joint. Over the span of years, the 
progressive accumulation of urate crystal and recurrent 
attack of inflammation leads to chronic destructive arthritis 
leading to different kind of deformities. 
The Vatarakta has attracted the attention of world’s 
scientists working on the problem, not only due to the 
problem faced by patient during acute attack but due to its 
remote complications and sequels. If the chronic condition is 
not treated properly, the deformity of joints and cartilages 
cripples a person throughout his life. 
Gout is more common in men than in women and more 
prevalent in black races than white. A number of factors have 
been found to influence rates of gout, including age, sex, race, 
and the season of the year. Gout is seen in only one-tenth of 
the patients of hyperuicaemia. The incidence of gout varies 
in population from 0.2 to 3.5 per 1000, with an overall 
prevalence of 2 to 26 per 1000. The prevalence of Gout has 
increased in recent years. It is rare in children and 
premenopausal females and the peak age of onset in male is 
between 40 years and 60 years. The chances of having gout 
raises with age in men, with a peak around 50 while in 
women, gout attacks usually occur after menopause. 
For the treatment of Vatarakta/Gouty Arthritis, along with 
different drugs for internal use, Acharya Charak has 
advocated the use of different ghrit yog, tail yog, lepa, 
pradeha, etc for external application in different types of 
Vatarakta for relieving pain, swelling, stiffness, burning, 
itching, etc. so for this research work we selected two 
medicines mentioned in Ayurvedic classics- 
1. Patoladi Kwath (Susrut Chikitsa -5/13) 
2. Rasnadi Pradeh (Charak Sutra -3/22) 
Aims and Objectives 
1. To establish an effective herbal formulation for 
Vatarakta/Gouty arthritis. 
2. To establish the efficacy of Patoladi Kwath & Rasnadi 
Pradeh in cases of Vatarakta/Gouty arthritis. 
3. To observe clinical improvement of the disease during 
the follow up period. 
4. To study any adverse effects of the trial drug. 
MATERIALS AND METHODS 
Protocol of Research 
1. I.E.C. Approval- Approving of synopsis for human trial 
was obtained from Institutional Ethical Committee of 
S.A.C. & Hospital, Lucknow, U.P. 
2. Consent- Written and informed consent of study 
subjects was taken before inclusion in the trial. 
3. Proforma- Proforma incorporating detailed profile of 
study subjects with complaining history, signs and 
symptoms and assessment was prepared. 
Selection of Patients 
For purpose of this clinical trial, patients of Vatarakta (Gouty 
Arthritis) were selected regardless of sex, religion, 
occupation and socio-economic conditions, with the age 
group of 21-60 year from O.P.D. & I.P.D. of State Ayurvedic 
College & Hospital, Lucknow and the referred cases which 
fulfill criteria of our clinical proforma were also included. 
After careful clinical history, examination & laboratory 
investigations as per proforma, patients were selected and 
screened for their suitability of getting enrolled in this 
clinical trial as per specific inclusion and exclusion criteria. 
Inclusion Criteria 
1. The patients of Vatarakta having serum uric acid >7 mg/dl 
in males & >5.7 mg/dl in females and at least 3 of the 4 
essential symptoms with or without nonessential 
symptomatology. 
2. Sex : Both male & female. 
3. Socioeconomic status : All 
4. Age : 21-60 years 
5. Patient willing to sign the consent.  
Exclusion Criteria of the Patient 
1. Patients below 21 year and above 60 years of age. 
2. Complicated cases of Vatarakta by other chronic systemic 
disorders like RA, OA, SLE, Diabetes, Tuberculosis, Renal 
disease, Hepatic diseases. 
3. Complicated cases of Vararakta by its Updravas like 
Hikka, Moorchha, Moha, Visarpa, Mansa-Koth, 
Angulivakrata etc. 
4. Complicated cases of gout with Chronic joint deformity, 
marked dysfunction, discharging tophi, etc. 
5. Pregnancy and lactation. 
6. Patients not willing to sign the consent. 
Criteria for Withdrawal 
1. Personal matters 
2. Aggravation of complaints 
3. Inter current illness 
4. Any other difficulties 
5. Will of the patient 
Symptoms 5  
Essential Symptoms- 
1. Sandhishu Ruk (pain in the affected joint) 
2. Sandhishu Rag (redness in the affected joint) 
3. Sandhishu Swathu (swelling in the affected joint) 
4. Sparsh-asahatvam (tenderness in affected area) 
Nonessential Symptoms- 
1. Sandhishu Kathinya (Stiffness / decreased / restricted 
movements of joint) 
2. Sandhishu Twagbahaya Tamra (Discoloration of skin of 
affected area) 
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3. Sandhishu Kandu (Itching in affected joint) 
4. Sandhishu Daha (Burning sensation over joint)  
Investigations- 
 Blood– TLC , DLC , Hb% , ESR 
 Urine- Routine (R) and Microscopic (M) 
 Serum Uric Acid 
 R.A. Factor 
 Liver Function Test- Sr. Bilirubin, SGOT, SGPT, Sr. 
Alkaline Phosphatase 
 Renal Function Test- Blood Urea, Sr. Creatinine 
 Blood Sugar -  F/PP 
 X-ray of involved joint (if possible)- AP view and 
Lateral view  
 Synovial Fluid Analysis (if possible) 
Contents of Formulations- 
1. Patoladi Kwath6- it contains Patol Patra, Trifla 
(Haritaki, Vibhitaki, Amalki), Satavari, Guduchi & Katuka. 
2. Rasnadi Pradeh7- it contains Rasna Patra, Guduchi, 
Yastimadhu, Bala, Atibala, Vidari Kanda, Godugdha, 
Goghrita and Madhuchhista (bee-wax). 
Preparation and Packing of the Trial Drugs 
All the drugs mentioned above was taken from the central 
drug store of State Ayurvedic College & Hospital, Lucknow 
and from nearby market. All the ingredients were then 
authenticated by the Department of Dravyaguna State 
Ayurvedic College & Hospital, Lucknow. 
The drugs, Patoladi Kwath and Rasnadi Pradeh were then 
prepared according to the classical drug preparation method 
described in the text by the department of Rasashastra & 
Bhaisajyakalpana State Ayurvedic College & Hospital, 
Lucknow. 
Patoladi Kwath 
Preparation and packing- 
Dried contents were taken in equal ratio. Yavkut was done & 
packed in 600 gm packs for 15 days. Patients were advised to 
make Kwath at home by classical method as told by Acharya 
Sharangadhara8. 
Rasnadi  Pradeh 
In this Yog, instead of Jeevak and Risbhak, Vidari Kand was 
taken, as these two drugs are not available in present time 
and according to Acharya Bhav Prakash9 due to similar 
properties (Gudaistat-tulyam) Jeevak and Risbhak can be 
substituted by Vidari. So instead of one part Jeevak and one 
part Risbhak, two parts of Vidari Kand was taken. 
Ratio of Ingredients- 
1. Rasna  1 part  
2. Guruchi  1 part  
3. Yastimadhu  1 part  
4. Bala   1 part  
5. Atibala  1 part  
6. Vidari kand  2 part  
7. Goghrit  8 part  
8. Godugdha   32 part 
9. Jala     32 part   
10. Madhuchhista   1 part  
Preparation and packing – 
The Pradeh (Ghrit Yog) was prepared according to the 
classical method given by the Acharya Sharangdhar10 and 
then bee wax was added in ratio equal to one of the 
ingredient of Kalka Dravya. After Samyak Paka it was 
drained and decanted into a container through a filter and 
the final product “Rasnadi Pradeh” was packed in well for 15 
day in 100 ml container.  
Type of Study:  Phase-2, Rational, Randomized (sequential 
pattern) Parallel group study. 
Period OF Study: Total duration of clinical trial is of 90 days. 
Sample Size: Total 56 patients were registered including 6 
dropouts. 
Grouping of the Patients and Drug Administration- All 
the selected patients registered for the clinical trial were 
divided in two groups- 
1) Group A: In group-A 25 patients were kept on- 
i. Patoladi Kwath- 40 ml Kwath 2 times a day after meal. 
Duration- 90 days 
Follow up- At every fortnight from day of registration till 
day 90  
2) Group B : In group B-25 patients were kept on- 
i. Patoladi Kwath- 40 ml Kwath 2 times a day after meal. 
ii. Rasnadi Pradeh- about 2 mm thick Pradeh was applied 
over the affected joint in the evening. 
Duration - 90 days 
Follow up – At every fortnight from day of registration till 
day 90.  
The assessment of subjective and objective parameters for 
each patient was done on 0th, 15th, 30th, 45th, 60th, 75th and 
90th day. 
Parameter for Assessment of Clinical Symptomatology: 
(A). Subjective Parameters: 
All the subjective parameters were graded 0, 1, 2, 3 (nil, mild, 
moderate & severe) on the basis of its intensity & severity 
given by patients on history taking & confirmed by clinical 
examination before starting the trial drugs. 
B). Objective Criteria: 
The quantitative analysis of the values of the Serum Uric 
Acid and ESR were done before & after the treatment and 
during the follow up to compare the inflammatory condition 
of the affected joints. 
Criteria for assessment of result: 
The results of the treatment were accessed on the basis of 
improvement in terms of: 
1. Symptomatic Relief 
2. Improvement in terms of Lab investigation i.e, decrease in 
Serum Uric Acid level and ESR value. 
RESULT 
The results of the present clinical trial were grouped as 
follows: 
1) Relieved: 
1) Patients having> 75% relief in terms of symptoms. 
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ii) Normal range of pathological findings. 
2) Improved: 
i) Patients having improvement between 40-75% in clinical 
symptoms 
a) Mild Improvement- Improvement between 40- <57.5% 
in clinical symptoms 
b) Moderate Improvement- Improvement between 57.5-
75% in clinical symptoms 
ii) Pathological findings are improved but not within normal 
limit and may be up to higher side. 
3) Unchanged: 
i) Patients having improvement less than 40% in terms of 
clinical symptoms. 
ii) Pathological findings remain same as before trial. 
iii) Disease may reoccur. 
4) Worsened: 
i) Patients having no improvement in terms of clinical 
symptoms. 
ii) Pathological findings gets disturbed (serum uric acid level 
may get increased). 
iii) Disease may get worsen or symptoms may increased. 
Statistical tools: 
The information gathered based on observation made about 
various parameters were subjected to statistical analysis in 
terms of Mean (X) and Standard Deviation (SD). 
For intragroup comparison Wilcoxon signed rank test and 
Paired t-test were used while for intergroup comparison 
Mann Whitney test and Unpaired t-test were used. The 
results calculated were interpret as below- 
 Not significant : P > 0.05 
 Significant  : P < 0.05 
 Very significant : P < 0.01 
 Extremely significant : P <0.001 
Observations 
(a) Demographic observations-  
For the trial total 56 patients were registered. The 
demographic data was assessed for all the patients- 
Patients were selected from age group of 21 to 60 years. It 
was found that the age group of 41 to 50 years comprises the 
maximum number of patients 21 (37.5%) followed by 20 
(35.7%) from the age group 31 to 40 years and 11 (19.6%) 
from the age group 51 to 60 years while 21 to 30 years of age 
group have least number of patients 4 (7.1%). According to 
sex, 33 (58.9%) patients were male and 23 (41.1%) patients 
were female. Considering the relationship of the disease with 
the religion 44 (78.6%) patients were Hindu and 12 (21.4%) 
were Muslims and out of 56 patients 53 (94.60%) were 
married. 
Occupation, educational status, economic status, residential 
& environmental condition plays a very important role in the 
causation of disease. 17 (30.405) were from service class, 18 
(32.10%) from business class, 18 (32.10%) were housewives 
& only 3 (5.45) were students. Out of total 94.60% (53) 
patients were literate. High-income group were 34 (60.70%), 
medium class were 19 (34.0%) & only 3 (5.3%) were poor. 
Most of the patients 53 (94.60%) were from urban area 
which strongly supports that Vatarakta is a disease of 
affluent people which supports its synonym ‘Adhayavata’ of 
Acharya Charak.  
Considering the diet and addiction habits of the patients, it 
was observed that 19 (33.90%) patients were vegetarian and 
37 (66.10%) were having mixed diet pattern of diet. Out of 
56 patients, 23 patients were having no addiction, 24 
patients were addicted to tea/coffee, 9 were addicted to 
smoking, 8 were alcoholic and only 2 patients were addicted 
to tobacco chewing.  
Considering the Deha Prakriti of the patients 26 (46.40%) 
were Vata-Pittaj, 19 (33.90%) patients were Pitta-Kaphaj 
and 11 (19.70%) patients were of Vata-Kaphaj Prakriti. 
State of Agni and Kostha Prakriti when assessed before the 
trial, 34 (60.70%) patients were having Vishamagni, 11 
(19.60%) had Mandagni, 7 (12.50%) patient had Samagni 
and only 4 (7.2%) had Tikshnagni. Out of 56 patients, 39 
(69.70%) had Madhyama Kostha, 11 (19.60%) had Mridu 
Kostha and 6 (10.70%) had Krura Kostha. Among these 
patients 23 (41.10%) had irregular bowel habit, 19 (33.90%) 
had regular bowel habit, 8 (14.70%) patient had tendency to 
pass hard stool while 6 (10.70%) passes loose stool.  
Considering nature of work predominantly performed by 
patients and pattern of exercise they execute, working 
pattern of 21 (37.50%) were of standing nature, sitting in 18 
(32.10%), walking in 13 (23.20%) and travelling type of 
work in only 4 (7.20%) patients. Among these patients 29 
(51.80%) do not perform exercise, 20 (35.70%) perform 
exercise irregularly while only 7 (12.50%) patients were 
performing regular exercise. 
Considering the associated illness and past history, 
maximum patients 39 (69.60%) had no associated illness, 
only 7 (12.50%) patient had hypertension and 7 (12.50%) 
had associated back pain & only 3 (5.4%) had 
hypothyroidism. 37 (66.0%) patient had no history of past 
illness, 11 (19.60%) patient had past history of Gout attack, 3 
(5.40%) had history of UTI, 2 (3.60%) had renal stone in 
past, 2 (3.60%) had history of trauma and only 1 (1.8%) 
patient had history of cholelithiasis.   
Considering the family history of disease, 15 (26.8%) patient 
had no family history of any disease but family history of 
gout in 14 (25.0%), osteoarthritis in 9 (16.0%), diabetes in 3 
(5.4%), rheumatoid arthritis in 1 (1.8%) and diabetes in 1 
(1.8%) patient as family history.   
Considering the nature of onset & pattern of involvement of 
joints, 31 (55.40%) patients were having sudden onset and 
25 (44.60%) were having insidious onset of disease. Ankle 
joint was the most common site of origin of disease, it was 
present in 22(46.8%) patients. 35 (62.50%) patients were 
having asymmetrical involvement of joint while 21 (37.50%) 
were having symmetrical involvement of joint. 
Considering the initial joint involvement, in 20 (35.7%) 
patients metatarsophalangeal joint (great toe) was first joint 
to get involved, knee joint in 12 (21.4%),  ankle joint in 11 
(19.7%), other phalangeal joints in 7 (12.5%) and wrist joint 
in 6 (10.7%) patient was first joint to get involved. 
(b) Clinical observations- 
Clinical Observation was done on 50 patients who completed 
the trial out of 56 patients selected and registered according 
to predetermined “Criteria of Selection”. 
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Table 1: Showing prevalence of sign and symptoms in 50 cases of Vatarakta before the use of trial drug 
S. No. Sign & Symptoms 
No. of Patients 
Total 
(n=50) 
Percentage Group-A 
(n=25) 
Group-B 
(n=25) 
1 
Sandhishu Ruk  
(Pain in the affected joint) 
25 25 50 100% 
2 
Sandhishu Rag 
(Redness in the affected joint) 
12 13 25 50% 
3 
Sandhishu Swathu 
(Swelling in affected joint) 
25 25 50 100% 
4 
Sparsh-asahatvam 
(Tenderness in affected area) 
25 25 50 100% 
5 
Sandhishu Kathinya 
(Decreased/Restricted movements of Joints) 
25 25 50 100% 
6 
Sandhishu Twagbahaya Tamra 
(Skin discoloration of affected area) 
6 8 14 28% 
7 
Sandhishu Kandu 
(Itching in the affected joint) 
10 12 22 44% 
8 
Sandhishu Daha 
(Burning sensation in affected joint) 
15 17 32 64% 
 
Result 
Result calculated for 50 patients, 25 in each group who completed the trial. We observed that action of the drugs was slow, 
steady & progressive. The trial drugs had shown the effect in almost all the symptomatology. Effect of trial drugs over various 
symptoms are as follows- 
Effect of therapy on SANDHISHU RUK (Pain in the affected joint)  
Table 2: Comparison of change in Sandhishu Ruk before and after the trial 
Time interval 
Group A (n=25) Group B (n=25) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 2.23 +0.48 2.36 +0.49 -0.23 0.82 
Day 90 0.72 +0.61 0.48 +0.59 1.26 0.21 
Mean Change 1.51+0.58 1.88+0.44   
% of relief 68.96% 79.66%   
Intra Group p-value2 < 0.0001* p-value2 < 0.0001*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
Effect of therapy on SANDHISHU RAG (redness in the affected joint)  
Table 3: Comparison of change in Sandhishu Rag before and after the trial 
Time interval 
Group A (n=12) Group B (n=13) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 2.00 +0.85 2.08 +0.64 0.19 0.85 
Day 90 0.42 +0.51 0.23 +0.44 -0.76 0.45 
Mean Change 1.58+0.79 1.85+0.55   
% of relief 79.00% 88.94%   
Intra Group p-value2 = 0.001* p-value2 = 0.0002*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
Effect of therapy on SANDHISHU SWATHU (Swelling in the affected joint)  
Table 4: Comparison of change in Sandhishu Swathu before and after the trial 
Time interval 
Group A (n=25) Group B (n=25) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 1.56 +0.58 1.68 +0.69 -0.47 0.63 
Day 90 0.32 +0.48 0.20 +0.41 0.72 0.47 
Mean Change 1.24+0.44 1.48+0.51   
% of relief 79.50% 88.10%   
Intra Group p-value2 < 0.0001* p-value2 < 0.0001*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
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Effect of therapy on SPARSH-ASHAHATVAM (Tenderness in the affected joint) 
Table 5: Comparison of change in Sparsh-asahatvam before and after the trial 
Time interval 
Group A (n=25) Group B (n=25) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 1.88 +0.73 2.12 +0.60 -1.12 0.26 
Day 90 0.56 +0.51 0.32 +0.56 1.55 0.12 
Mean Change 1.32+0.63 1.80+0.50   
% of relief 70.20% 84.90%   
Intra Group p-value2 < 0.0001* p-value2 < 0.0001*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
 
Effect of therapy on SANDHISHU KATHINYA (Decreased/ Restricted movements of the affected joint) 
Table 6: Comparison of change in Sandhishu Kathinya before and after the trial 
Time interval 
Group A (n=25) Group B (n=25) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 1.80 +0.41 1.96 +0.54 -0.81 0.41 
Day 90 0.52 +0.59 0.36 +0.59 0.92 0.36 
Mean Change 1.28+0.61 1.64+0.58   
% of relief 71.10% 81.63%   
Intra Group p-value2 < 0.0001* p-value2 < 0.0001*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
 
Effect of therapy on SANDHISHU TWAGBAHAYA TAMRA (Skin discoloration of affected area) 
Table 7: Comparison of change in Sandhishu Twagbahaya Tamra before and after the trial 
Time interval 
Group A (n=6) Group B (n=8) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 1.67 +0.52 1.88 +0.35 1.36 0.17 
Day 90 1.17 +0.41 0.88 +0.64 -0.71 0.48 
Mean Change 0.50+0.54 1.0+0.53   
% of relief 29.94% 53.20%   
Intra Group p-value2 = 0.25 p-value2 = 0.0156*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
 
Effect of therapy on SANDHISHU KANDU (Itching in the affected joint) 
Table 8: Comparison of change in Sandhishu Kandu before and after the trial 
Time interval 
Group A (n=10) Group B (n=12) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 1.30 +0.48 1.75 +0.62 1.51 0.13 
Day 90 0.40 +0.52 0.33 +0.49 -0.23 0.81 
Mean Change 0.90+0.32 1.42+0.51   
% of relief 69.23% 81.14%   
Intra Group p-value2 = 0.0039* p-value2 = 0.0005*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
 
Showing effect of therapy on SANDHISHU DAHA (Burning sensation in the affected joint)  
Table 9: Comparison of change in Sandhishu Daha before and after the trial 
Time interval 
Group A (n=15) Group B (n=17) Inter Group 
Mean +SD Mean +SD z-value1 p-value1 
Day 0 1.53 +0.64 1.59 +0.71 0.11 0.91 
Day 90 0.40 +0.51 0.24 +0.44 -0.77 0.44 
Mean Change 1.13+0.74 1.35+0.49   
% of relief 73.85% 84.94%   
Intra Group p-value2 = 0.0002* p-value2 < 0.0001*   
1Mann-Whtiney U test, 2Wilcoxon signed rank test, *Significant 
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Showing effect of therapy on SERUM URIC ACID (mg/dl)  
Table 10: Comparison of change in Serum Uric Acid (mg/dl) before and after the trial 
Time interval 
Group A (n=25) Group B (n=25) Inter Group 
p-value1 Mean +SD Mean +SD 
Day 0 8.43 +1.65 8.22 +1.47 0.64 
Day 90 6.68 +1.41 6.45 +1.13 0.53 
Mean Change 1.75+1.00 1.78+0.77  
% of Relief 20.76% 21.53%  
Intra Group 
t-value2 = 8.72 
p-value2 < 0.0001* 
t-value2 = 11.45 
p-value2 < 0.0001* 
 
1Unpaired t test, 2Paired t test *Significant 
Showing effect of therapy on ESR (mm/1st hrs. by Westerngreen Method) 
Table 11: Comparison of change in ESR before and after the trial 
Time interval 
Group A (n=25) Group B (n=25) Inter Group 
p-value1 Mean +SD Mean +SD 
0 Day 27.60 +4.43 28.40 +5.13 0.59 
90 Day 20.64 +4.15 21.36 +4.39 0.596 
Mean Change 6.69+2.71 7.04+2.83  
% of Relief 25.22% 24.79%  
Intra Group p-value2 < 0.0001* p-value2 < 0.0001*  
1Unpaired 2Paired t-test *Significant 
 
Showing effect of therapy on biochemical parameters 
Table N12: Comparison of change in biochemical parameters before and after the trial 
1. Hb (gm/dl) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 11.46 +0.90 11.40 +0.97 0.24 
AT 11.80 +0.82 11.68 +0.87 0.56 
Intra Group 
M.C. = -0.34+0.22 
p-value2 < 0.0001* 
M.C. = -0.28+0.28 
p-value2 <0.0001* 
 
2. ESR (mm/hr.) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 27.60 +4.43 28.40 +5.13 0.59 
AT 20.64 +4.15 21.36 +4.39 0.596 
Intra Group 
M.C. = 6.96+2.71 
p-value2 < 0.0001* 
M.C. = 7.04+2.83 
p-value2 < 0.0001* 
 
3. TLC (cells/mm3) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 10770 +1264.95 11070 +1105.59 0.56 
AT 10020 +824.35 10280 +1074.76 0.61 
Intra Group 
M.C. = 750+501.66 
p-value2 = 0.0011* 
M.C. = 790+430.63 
p-value2 = 0.0003* 
 
1Unpaired t-test 2Paired t-test *Significant, M.C.= Mean Change 
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Showing effect of therapy on DLC (Differential Leucocyte Count) 
Table 13: Comparison of change in DLC before and after the trial 
1. NEUTROPHILS (%) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 75.30 +3.59 77.00 +4.03 0.996 
AT 72.40 +2.22 73.20 +3.16 0.66 
Intra Group 
M.C. = 2.90+1.45 
p-value2 < 0.0001* 
M.C. = 3.80+2.75 
p-value2 = 0.0018* 
 
2. LYMPHOCYTES (%) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 22.70 +5.29 21.00 +4.00 0.81 
AT 25.90 +4.07 24.70 +2.98 0.75 
Intra Group 
M.C. = -3.20+1.81 
p-value2 = 0.0003* 
M.C. = -3.70+4.14 
p-value2 = 0.02* 
 
3. EOSINOPHILS (%) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 1.70 +0.95 0.90 +0.74 2.10 
AT 1.40 +0.52 1.10 +0.88 0.93 
Intra Group 
M.C. = 0.30+0.82 
p-value2 = 0.28 
M.C. = -0.20+0.92 
p-value2 = 0.51 
 
4. MONOCYTES (%) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 0.90 +0.74 0.50 +0.53 1.39 
AT 1.10 +0.74 0.70 +0.82 1.14 
Intra Group 
M.C. = -0.20+0.92 
p-value2 = 0.51 
M.C. = -0.20+0.42 
p-value2 = 0.17 
 
5. BASOLHILS (%) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 0.30 +0.48 0.20 +0.42 0.49 
AT 0.20 +0.42 0.30 +0.48 0.49 
Intra Group 
M.C. = 0.10+0.74 
p-value2 = 0.68 
M.C. = -0.10+0.57 
p-value2 = 0.59 
 
1Unpaired t-test 2Paired t-test *Significant, M.C= Mean Change 
 
Showing effect of therapy on Blood Sugar (F/PP) 
Table 14: Comparison of change in Blood Sugar (F/PP) before and after the trial 
1. Fasting B. Sugar (mg/dl) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 85.60 +13.19 84.00 +16.22 0.24 
AT 83.10 +12.88 81.00 +12.45 0.37 
Intra Group 
M.C.= 2.5+2.46 
p-value2 = 0.67 
M.C.= 3.0+6.05 
p-value2 = 0.15 
 
2. Post Prandial B. Sugar (mg/dl) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 140 +20.81 141 +19.71 0.15 
AT 133.50 +23.72 134 +18.38 0.12 
Intra Group 
M.C.= 6.5+5.10 
p-value2 = 0.003* 
M.C.= 6.8+4.24 
p-value2 = 0.0007* 
 
1Unpaired t-test 2Paired t-test *Significant, M.C.= Mean Change 
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Showing effect of therapy on Kidney Function Test (KFT) 
Table 15: Comparison of change in Kidney Function Test (KFT) before and after the trial 
1. B. Urea (mg/dl) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 27.56 +3.19 30.03 +5.84 1.17 
AT 24.54 +2.93 26.27 +5.02 0.99 
Intra Group 
M.C.= 3.02+1.32 
p-value2 < 0.0001* 
M.C.= 3.67+1.97 
p-value2 = 0.0002* 
 
2. S. Creatinine (mg/dl) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 0.95 +0.17 1.06 +0.29 1.04 
AT 0.86 +0.13 0.93 +0.18 0.99 
Intra Group 
M.C.= 0.09+0.10 
p-value2 = 0.019* 
M.C.= 0.13+0.19 
p-value2 = 0.03* 
 
1Unpaired t-test 2Paired t-test *Significant, M.C.= Mean Change 
 
Showing effect of therapy on Liver Function Test (LFT) 
Table 16: Comparison of change in Liver Function Test (LFT) before and after the trial 
1. S. Bilirubin (mg/dl) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 0.84 +0.26 0.79 +0.30 0.396 
AT 0.68 +0.14 0.70 +0.22 0.246 
Intra Group 
M.C.= 0.16+0.18 
p-value2 = 0.02* 
M.C.= 0.09+0.12 
p-value2 = 0.04* 
 
2. S. Alkaline Phosphatase (IU/L) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 208 +45.90 223 +49.62 0.71 
AT 175 +19.10 200.10 +42.12 1.71 
Intra Group 
M.C.= 33+32.27 
p-value2 = 0.01* 
M.C.= 22.90+17.09 
p-value2 = 0.002* 
 
3. SGOT (IU/L) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 30.10 +8.17 29.10 +8.28 0.27 
AT 27.40 +5.75 25.70 +4.85 0.71 
Intra Group 
M.C.= 2.7+3.37 
p-value2 = 0.03* 
M.C.= 3.4+4.11 
p-value2 = 0.028* 
 
4. SGPT (IU/L) 
Time interval 
Group A (n=25) Group B (n=25) Inter Group p-
value1 Mean +SD Mean +SD 
BT 27.90 +5.59 31.60 +3.78 1.73 
AT 24.10 +3.28 28.80 +2.35 3.68 
Intra Group 
M.C.= 3.8+3.46 
p-value2 = 0.007* 
M.C.= 2.8+1.62 
p-value2 = 0.0004* 
 
1Unpaired t-test 2Paired t-test *Significant, M.C.= Mean Change 
 
Overall assessment of the result: 
The result was assessed on the basic of symptomatic relief 
and improvement in terms of lab investigation. The efficacy 
of the drugs was divided in following categories- 
1. Relieved (>75% relieve in all terms) 
2. Moderate Improvement (75-57.5% relieve in all terms) 
3. Mild Improvement (<57.5-40% relieve in all terms) 
4. Unchanged (<40 % relief) 
5. Worsens
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Table 17: Overall assessment of patients after the treatment 
Group 
Relieved 
(>75% relief) 
Improved 
Unchanged 
(< 40% relief) 
Moderate 
(75-57.5% relief) 
Mild 
(<57.5-40% relief) 
No. of pts. % No. of pts. % No. of pts. % No. of pts. % 
Group A (n=25) 12 48.0% 7 28.0% 5 20.0% 1 4.0% 
Group B (n=25) 19 76.0% 4 16.0% 2 8% 0 0% 
 
In group ‘A’ 12 (48.0%) patients were relieved, 7 (28.0%) 
patients were moderately improved, 5 (20.0%) patient were 
mildly improved and 1 (4.0%) patient did not show any 
response by administration of drug therapy. 
In group ‘B’ 19 (76.0%) patients were relieved, 4 (16.0%) 
patients were moderately improved, 2 (8.0%) patient were 
mildly improved by administration of drug therapy. There 
was no case recoded in unchanged group and worsen group. 
The overall relived was higher in group ‘B’ (76.0%) 
compared to group ‘A’ (48.0%). The moderately improved 
class was higher in group ‘A’ (28.0%) than group ‘B’ (16.0%) 
also the mildly improved class was higher in group ‘A’ 
(20.0%) than group ‘B’ (8.0%). In group ‘A’ one patient was 
recorded as unchanged while no patient was recorded as 
unchanged in group ‘B’. 
 
 
Graph 1: Showing overall assessment of patients after treatment in both the groups 
DISCUSSION 
Aim of this clinical trial entitled as “A clinical study to 
evaluate the efficacy of Patoladi Kwatha (Su. Chi.) with & 
without Rasnadi Pradeh (Ch. Su.) in cases of Vatarakta (w.s.r. 
to Gouty arthritis)” was to do comparative clinical evaluation 
of Rasnadi Pradeh as local application in cases of Vatarakta 
with special reference to gouty arthritis. Result calculated for 
50 patients, 25 in each group who completed the trial. We 
observed that action of the drugs was slow, steady & 
progressive. The trial drug  in both group had shown the 
effect in almost all the symptomatology but the overall relief 
was higher in group ‘B’ 
 
Table 18: Summarization of improvement in all features 
S. N. Features 
Percentage of relief 
Group A Group B 
1. Sandhishu Ruka  
(Pain in the affected joint) 
68.96 % 79.66 % 
2. Sandhishu Raga 
(Redness in the affected joint) 
79.00 % 88.94 % 
3. Sandhishu Swathu 
(Swelling in affected joint) 
79.50% 88.10 % 
4. Sparsh-ashatvam 
(Tenderness in affected area) 
70.20 % 84.90 % 
5. Sandhishu Kathinya 
(Decreased/Restricted movements of Joints) 
71.10 % 81.63 % 
6. Sandhishu Twagbahaya Tamra 
(Skin discoloration of affected area) 
29.94 % 53.20 % 
7. Sandhishu Kandu 
(Itching in the affected joint) 
69. 23 % 81.14 % 
8. Sandhishu Daha 
(Burning sensation in affected joint) 
73.85 % 84. 94 % 
9. Serum Uric acid (mg/dl) 20.76 % 21.53 % 
10. ESR mm/1st hrs. (Westerngreen Method) 25.22 % 24.79 % 
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Graph 2: Showing Percentage of improvement in different Features  
 
Probable mode of action of Trial drugs: 
In Ayurveda, the action of the drug is determined by 
Pharmacodynamic factors like Rasa, Guna, Veerya and Vipaka 
and some special property called as Prabhava, which cannot 
be explained on by four pharmacodynamic factors. These 
factors work against the Dosha and Dushya to break the 
pathogenesis (Samprapti Vighatana) causing relief in 
symptoms.  
1. Patoladi Kwath- 
Contents – Patol Patra, Trifla (Haritaki, Vibhitski, Amalki), 
Satavari, Guduchi & Katuki. 
 
 
Table 19: Properties of different ingredients of the Patoladi Kwath                  
Name of 
drug 
Patol Amalaki Haritaki Vibhitaki Satavari Guruchi Kutki 
Latin name 
Trichosanthes 
dioica 
Emblica 
offcinalis 
Terminalia 
chebula 
Terminalia 
bellirica 
Asparagus 
racemosus 
Tinospora 
cordifolia 
Picrorhiza 
kurroa 
Family Cucurbitaceae Euphorbiaceae Combretaceae Combretaceae Liliacae Menispermaceae Scrophulariacae 
Part used Leaf Fruit Fruit Fruit Root Stem stem 
Rasa Tikta 
Pancha rasa 
except lavana, 
amla rasa 
pradhan 
Pancha rasa 
except 
lavana,kashaya 
rasa pradhan 
Kashaya 
Madhur,  
Tikta 
Tikta,  Kashaya Tikta 
Guna Laghu, ruksha 
Guru, ruksha , 
sheet 
Laghu, ruksha Ruksha, laghu 
Guru, 
snigdh 
Guru, snigdh Ruksha, laghu 
Veerya Ushna Sheet Ushna Ushna Sheet Ushna Sheet 
Vipak 
 
Katu Madhur Madhur Madhur Madhur Madhur Katu 
Chemical 
properties 
___ 
 
Gallic acid, 
Tannic acid 
Calcium, Vit-C 
Chebulagic    
acid, 
Chebulinic 
acid 
Chebulic acid,  
Gallic acid,    
Tannic      acid 
Saponln 
Berberin, 
Geloin 
Picrorhizin, 
Kutkin, Kutkiol, 
Kutikisterol 
Prabhav 
(special 
action) 
Saravdosh 
shamak 
Saravdosh 
shamak 
mainly pitta 
shamak 
Saravdosh 
shamak mainly 
vatashamak 
Saravdosh 
shamak 
mainly 
kaphashamak 
Vata pitta 
shamak 
Saravdosh 
shamak mainly 
pitta shamak 
Kaph pitta 
shamak 
 
 
 
Patol Patra is Pitta Shamak, Haritaki is Vatarakta Nashak & 
has anti-arthritic action11. Vibhitaki cures Dhatu-Gata Dosha 
& has analgesic effect12. Amalki is a Rasayan, Pitta Shamak, 
uricosuric due to presence of Vit-C & causes 
immunomodulation13. Satavari is Balya & Vata-Pitta-Rakta 
Janya Shopha Nashak, has anti-urolithic action14 & causes 
immunomodulation15, Guduchi is best drug to cure Vatarakta, 
it is Tridosh Shamak, it contains Tinosporin which has anti-
uremic action16 & its anti-inflammatory action resemble to 
NSAIDs17. Katuki is Lekhaniya & Bhedaniya which eliminates 
Doshas from the body, has Shoth, Daha, Kusth Nashak 
property & has anti-inflammatory property18. 
2. Rasnadi Pradeh- 
Contents– Rasna Patra, Guduchi, Yastimadhu, Bala, Atibala 
And Vidari  
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Table 20: Properties of different ingredients of the Rasnadi Pradeh 
Name of drug Rasna Guruchi Yastimadhu Bala Atibala Vidari 
Latin name Pluchea 
lanceolata 
Tinospora 
cordifolia 
Glycyrrhiza 
globera 
Sida  cordifolia Abutilon 
indicum 
Pueraria 
tuberosa 
Family Compositae Menispermaceae Leguminosae Malvaceae Malvaceae Leguminosae 
Part used Leaf Stem Root Root Root Rhizome 
Rasa Tikta Tikta, kashaya Madhur Madhur Madhur Madhur 
Guna Guru Guru, snigdha Guru, snigdha Laghu,  snigdha, 
picchil 
Laghu,  
snigdha, picchil 
Guru, snigdha 
Veerya Ushna Ushna Sheet Sheet Sheet Sheet 
Vipak Katu Madhur Madhur Madhur Madhur Madhur 
Chemical 
properties 
Quersitine, 
Isoraimnetin, 
Pluchin 
Berberin, Giloin Glycyrrhizin, 
Isoliquiritin, 
Liquiritin,  
Asparagin 
Ephedrine, 
Sterol, 
Phytosterol 
Asparagin Carbohydrate 
Prabhav 
(special 
action) 
Vata kapha 
shamak 
Saravdosh 
shamak mainly 
pitta shamak 
Vata pitta 
shamak 
Vata pitta 
shamak 
Vata pitta 
shamak 
Vata pitta 
shamak 
 
It was used for local application. Rasna is best Vata Shamak 
drug, it is Shotha, Shoola & Vedanahar. Guduchi is best drug 
to cure Vatarakta, it is Tridosh Shamak and contains 
Tinosporin whose anti-inflammatory action resemble to 
NSAIDs17. Yastimadhu is a potent Shopha & Shotha Nashak, 
has good anti-inflammatory19 & analgesic action20 when used 
locally. Bala & Atibala both are Balya, Vatahar, Vatarakta 
Nashak & has anti-inflammatory, analgesic property21,22. 
Atibala also has good anti-arthritic action23. Vidari Kand is 
Balya, Vata-Pitta-Rakta Janya Shoph Nashak, Daha Shamak, 
Mutral & has immunomodulatory action24. Godugdha and 
Goghrit both are Vatapitta & Daha Shamak. Madhuchhista is a 
potent Vatarakta Nashak & also cures Kandu, Kustha & 
Vrana.  
Due to above properties both the selected drugs seem to be 
effective in Vatarakta.  
CONCLUSION 
 The drugs used in Trial are Patoladi Kwath which was 
given orally in both the groups and Rasnadi Pradeh 
which was given for local application in group B only.  
 The trial drugs were given in 50 selected patients (25  in 
each group)  & it was observed that the effect of drugs 
was high on the symptoms of pain (Sandhishu Ruk), 
redness (Sandhishu Rag), swelling (Sandhishu Swathu), 
tenderness (Sparsh-ashahatvam), stiffness (Sandhishu 
Kathinya), itching (Sandhishu kandu) and burning 
sensation (Sandhishu daha). Grade of all these 
symptoms shows statistically significant (p<0.05) 
decrease in both the groups but the response was 
slightly higher in group ‘B’ than group ‘A’. 
 Rasnadi Pradeh is useful in cases of both Acute Gouty 
Arthritis as well as Chronic Gouty Arthritis because 
along with good result in pain, redness, swelling it also 
showed good result in itching & discoloration. 
 Estimation of change in Serum Uric acid (Percent 
change of 20.67% in group A & 21.53% in group B) & 
ESR (Percent change of 25.22% in group A & 24.79% in 
group B) was statistically significant in both the groups.  
 The trial drugs probably showed- analgesic 
(Vednahara), anti-inflammatory (Shothahara), blood 
purifier (Rakta Prasadak), immunomodulator, 
uricosuric effects, etc. Drug used for local application 
also showed good effect on Daha (burning), Kandu 
(itching), etc. 
 Trial drugs were well accepted & tolerated with good 
positive response except increased frequency of passage 
of stool in few cases. Probably Haritaki and Katuki in 
Patoladi Kwath has slight kostha sodhak property due 
to which 2 patient having mandagni and loose type of 
bowel habit complained of increased frequency of 
passage of stool & hence were withdrawn. So the dose of 
the drug should be titrated according to nature of 
kosthagni, type of kostha and type of bowel habit of 
patient in further trial. Other than increased frequency 
of passage of stool in few cases, the trial drug did not 
show any other major side effect regarding clinical and 
pathological parameters. 
 It is suggested that both the drugs should be tested in 
large scale for the long duration trial and these drugs 
may prove a valuable contribution from Ayurveda 
towards the ailing humanity. 
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